CATX Valuation

Perspective Therapeutics Inc

Add to Watchlist

Advanced Chart

3.970

-0.18(-4.337%)1D

Overview
Forecast
Valuation
Earnings

CATX Relative Valuation

CATX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CATX is overvalued; if below, it's undervalued.

Historical Valuation

Perspective Therapeutics Inc (CATX) is now in the Fair zone, suggesting that its current forward PS ratio of 528.88 is considered Fairly compared with the five-year average of -14.20. The fair price of Perspective Therapeutics Inc (CATX) is between 0.24 to 4.14 according to relative valuation methord.

Relative Value

Fair Zone

0.24-4.14

Current Price：3.97

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.13

P/B

Median3y

1.55

Median5y

2.34

-32.50

FCF Yield

Median3y

-17.64

Median5y

-13.57

Competitors Valuation Multiple

The average P/S ratio for CATX's competitors is 90.46, providing a benchmark for relative valuation. Perspective Therapeutics Inc Corp (CATX) exhibits a P/S ratio of 528.88, which is 484.68% above the industry average. Given its robust revenue growth of 5.23%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CATX.A

Perspective Therapeutics Inc

528.88

Average P/S: 90.46

5.23%